Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24142430 | 0.92 | LTA4H (0.46) | LTA4HKCNH2CYP2D6CYP2C9USP2 | |
| SCHEMBL4485447 | 0.85 | MAOB (0.44) | HDAC6 | |
| SCHEMBL25808654 | 0.85 | SMN1; SMN2 (0.47) | LMNAKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL25808664 | 0.83 | RAB9A (0.43) | LMNAUSP2KMT2AALDH1A1NPC1 | |
| SCHEMBL23500484 | 0.82 | LMNA (0.47) | LMNAKMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30768239 | 0.82 | LMNA (0.47) | LMNAKMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24143191 | 0.82 | LMNA (0.35) | LTA4HLMNAHDAC6USP2KMT2A | |
| SCHEMBL26735216 | 0.80 | GBA1 (0.37) | LMNAKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL24923066 | 0.80 | MMP1 (0.37) | LMNAHDAC6USP2KMT2AALDH1A1 | |
| SCHEMBL25760237 | 0.80 | MMP1 (0.35) | LMNAUSP2KMT2AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219941-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230126415-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-11566023-B2 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof | AKAGERA MEDICINES, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210403463-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403463-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | OXA1L, THPO, TBCD | LTA4H 273/4885KCNH2 3437/4885CYP2D6 329/4885 |
| US-20230126415-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | OXA1L, THPO, TBCD | LTA4H 273/4885KCNH2 3437/4885CYP2D6 329/4885 |
| US-20230219941-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF | OXA1L, THPO, TBCD | LTA4H 268/4885KCNH2 3372/4885CYP2D6 382/4885 |
| US-11566023-B2 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof | OXA1L, THPO, TBCD | LTA4H 273/4885KCNH2 3437/4885CYP2D6 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.